<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075255</url>
  </required_header>
  <id_info>
    <org_study_id>D3250C00020</org_study_id>
    <nct_id>NCT02075255</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS
      in systemic corticosteroid dependent patients with severe refractory asthma with elevated
      eosinophils.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2014</start_date>
  <completion_date type="Actual">August 8, 2016</completion_date>
  <primary_completion_date type="Actual">August 8, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control</measure>
    <time_frame>Week 28</time_frame>
    <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control</measure>
    <time_frame>Week 28</time_frame>
    <description>Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils &gt;=300/uL</measure>
    <time_frame>Week 28</time_frame>
    <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</measure>
    <time_frame>Week 28</time_frame>
    <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</measure>
    <time_frame>Week 28</time_frame>
    <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.</measure>
    <time_frame>Week 28</time_frame>
    <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control</measure>
    <time_frame>Week 28</time_frame>
    <description>Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Patients With ≥1 Asthma Exacerbation</measure>
    <time_frame>Immediately following the randomisation through Study Week 28</time_frame>
    <description>Number and percentage of patients with at least one post randomisation asthma exacerbation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Asthma Exacerbation</measure>
    <time_frame>The time from randomisation to the date of first asthma exacerbation over 28 weeks</time_frame>
    <description>Time to the first occurrence of asthma exacerbation post randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit</measure>
    <time_frame>The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.</time_frame>
    <description>Time to the first exacerbation requiring hospitalization or ER visit post randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Annualized Rate of Asthma Exacerbation</measure>
    <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
    <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization</measure>
    <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
    <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in Hospital Due to Asthma</measure>
    <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
    <description>Number of days in hospital due to asthma, if none, 0 day is considered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Pre-bronchodilator FEV1</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Asthma Symptom Scores (Total)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Rescue Medication Use</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of day inhaler puffs + 2 x [number of day nebulizer times].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 28 in ACQ-6</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ-6 Responders (Improvement) at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>Improvement is defined as ACQ-6 (End of treatment - baseline) &lt;= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) &gt;= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)</measure>
    <time_frame>Change from baseline at week 28</time_frame>
    <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AQLQ(s)+12 Responders (Improvement) at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)&gt;=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) &lt;= -0.5.
Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of Exposure</measure>
    <time_frame>From first dose to Week 24</time_frame>
    <description>Duration of exposure from first dose date to last dose date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Benralizumab</measure>
    <time_frame>Pre-first dose to Week 36</time_frame>
    <description>Pre-dose serum concentrations at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody Response</measure>
    <time_frame>From baseline to follow-up Week 36</time_frame>
    <description>Number and percentage of patients in different ADA response categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Blood Eosinophil Counts</measure>
    <time_frame>Change from baseline at Week 28</time_frame>
    <description>Percent change from baseline in blood eosinophil counts at week 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity</measure>
    <time_frame>From baseline to Week 28</time_frame>
    <description>Change from baseline in total lung capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume</measure>
    <time_frame>From baseline to Week 28</time_frame>
    <description>Change from baseline in residual volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity</measure>
    <time_frame>From baseline to Week 28</time_frame>
    <description>Change from baseline in vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity</measure>
    <time_frame>From baseline to Week 28</time_frame>
    <description>Change from baseline in functional residual capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity</measure>
    <time_frame>From baseline to Week 28</time_frame>
    <description>Change from baseline in inspiratory capacity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab administered subcutaneously every 4 weeks</description>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneously on study week 0 until study week 24 inclusive.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.</description>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Female and male aged from 18 to 75 years, inclusively.

          3. History of physician-diagnosed asthma requiring treatment with medium dose ICS and
             LABA.

          4. Elevated level of peripheral blood eosinophil

          5. Documented treatment with high-dose ICS and LABA for at least 6 months prior to Visit
             1

          6. Chronic oral corticosteroid therapy for at least 6 continuous months directly
             preceding Visit 1. Subjects must be on doses equivalent to 7.5 - 40 mg/day of
             prednisolone/prednisone at Visit 1 and be on a stable dose for at least 2 weeks prior
             to randomization. Patients must agree to switch to study required
             prednisone/prednisolone as their oral corticosteroid for the duration of the study.

          7. Patients with documented failures of OCS reduction within 6 months prior to Visit 1
             will not be required to proceed through the dose optimization phase during run-in.

          8. Morning pre-bronchodilator (Pre-BD) FEV1 of &lt;80% predicted

          9. Evidence of asthma as documented by either:

             Airway reversibility (FEV1 ≥12% and 200 mL) demonstrated at Visit 1, Visit 2, or Visit
             3 using the Maximum Post-bronchodilator Procedure OR Documented reversibility in the
             previous 24 months prior to Visit 1 OR Airway hyperresponsiveness (PC20 FEV1
             methacholine concentration ≤8mg/mL) documented in the previous 12 months prior to
             planned date of randomization OR Airflow variability in clinic FEV1 ≥20% between 2
             consecutive clinic visits documented in the 12 months prior to the planned date of
             randomization (FEV1 recorded during an exacerbation should not be considered for this
             criterion).

             All patients must have reversibility testing performed before randomization to
             establish a baseline characteristic.

             If patients do not demonstrate airway reversibility at either Visit 1 or Visit 2 and
             this is needed to qualify the patient for randomization, the site should reiterate the
             need to withhold short- and long-acting bronchodilators prior to Visit 3 in an effort
             to meet this inclusion criterion.

         10. At least 1 documented asthma exacerbation in the previous 12 months prior to the date
             informed consent is obtained

         11. Optimized OCS dose reached at least 2 weeks prior to randomization

         12. Additional asthma controller medication must not have been initiated during run
             in/optimization period (not applicable for management of exacerbations during
             screening/ run in optimization phase)

         13. At least 70% compliance with OCS use

         14. At least 70% compliance with usual asthma controller ICS-LABA

         15. Minimum 70% (i.e. 10 of 14 days) compliance with asthma daily diary (morning and
             evening diary)

        Exclusion criteria:

          1. Clinically important pulmonary disease other than asthma or ever been diagnosed with
             pulmonary or systemic disease, other than asthma, that are associated with elevated
             peripheral eosinophil counts.

          2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
             hematological, psychiatric, or major physical impairment that is not stable in the
             opinion of the Investigator and could:

               -  Affect the safety of the patient throughout the study

               -  Influence the findings of the studies or their interpretations

               -  Impede the patient's ability to complete the entire duration of study

          3. Acute upper or lower respiratory infections requiring antibiotics or antiviral
             medication within 30 days prior to the date informed consent is obtained or during the
             screening/run-in period

          4. Any clinically significant abnormal findings in physical examination, vital signs,
             hematology, clinical chemistry, or urinalysis during run-in/optimization period, which
             in the opinion of the Investigator, may put the patient at risk because of his/her
             participation in the study, or may influence the results of the study, or the
             patient's ability to complete entire duration of the study

          5. History of life-threatening asthma

          6. Asthma control reached at an OCS dose of ≤5mg during run-in/OCS optimization phase

          7. Qualifies for 3 consecutive dose reductions at Visits 2-4 and continues to meet OCS
             dose reduction criteria at Visit 5

          8. Receipt of oral corticosteroids, other than prednisone or prednisolone, as the
             maintenance oral steroid controller for asthma symptoms from Visit 1 and throughout
             the study.

          9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times
             the upper limit of normal (ULN) confirmed during screening period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Nair, MD,PhD,FRCP,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Joseph's Healthcare Hamilton Firestone Institute for Respiratory Health 50 Charlton Avenue East Hamilton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florida</city>
        <zip>1638</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrich</city>
        <zip>2850</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancagua</city>
        <zip>2820000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talca</city>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>20927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>02559</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karczew</city>
        <zip>05-480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koszalin</city>
        <zip>75-679</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubin</city>
        <zip>59-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>İstanbul</city>
        <zip>34844</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2559&amp;filename=Nair_ZONDA_CSP_REDACTED.pdf</url>
    <description>CSP redacted</description>
  </link>
  <reference>
    <citation>Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.</citation>
    <PMID>28530840</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>July 24, 2017</results_first_submitted>
  <results_first_submitted_qc>September 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>369 participants signed informed consent. 271 entered run in/OCS optimization period. 220 participants were randomized to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 220 patients randomised, all (100.0%) received treatment with study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="12.0"/>
                    <measurement group_id="B2" value="52.9" spread="10.1"/>
                    <measurement group_id="B3" value="49.9" spread="11.7"/>
                    <measurement group_id="B4" value="51.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control</title>
        <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control</title>
          <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set</population>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="50.00" upper_limit="83.30"/>
                    <measurement group_id="O2" value="75.00" lower_limit="60.00" upper_limit="87.50"/>
                    <measurement group_id="O3" value="25.00" lower_limit="0.00" upper_limit="33.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>33.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.70</ci_lower_limit>
            <ci_upper_limit>50.00</ci_upper_limit>
            <estimate_desc>Hodges-Lehmann estimate is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>37.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.80</ci_lower_limit>
            <ci_upper_limit>50.00</ci_upper_limit>
            <estimate_desc>Hodges Lehmann estimate is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control</title>
        <description>Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control</title>
          <description>Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change or any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>proportional odds model</method>
            <method_desc>Controlling for treatment group, region, and baseline OCS dose.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>7.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>proportional odds model</method>
            <method_desc>Controlling for treatment group, region, and baseline OCS dose.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>7.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils &gt;=300/uL</title>
        <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set, baseline blood eosinophil &gt;=300/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils &gt;=300/uL</title>
          <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set, baseline blood eosinophil &gt;=300/uL</population>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="60.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="75.00" lower_limit="60.00" upper_limit="91.70"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="28.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>50.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.00</ci_lower_limit>
            <ci_upper_limit>66.70</ci_upper_limit>
            <estimate_desc>Hodges Lehmann estimate is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>50.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.00</ci_lower_limit>
            <ci_upper_limit>66.70</ci_upper_limit>
            <estimate_desc>Hodges Lehmann estimate is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</title>
        <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</title>
          <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>7.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</title>
        <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set, eligible for 100% reduction (ie, patients with baseline OCS dose &lt;= 12.5 mg)</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control</title>
          <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose–final dose)/baseline dose}*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set, eligible for 100% reduction (ie, patients with baseline OCS dose &lt;= 12.5 mg)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>14.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>11.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.</title>
        <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.</title>
          <description>Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control</title>
        <description>Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control</title>
          <description>Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>5.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Patients With ≥1 Asthma Exacerbation</title>
        <description>Number and percentage of patients with at least one post randomisation asthma exacerbation.</description>
        <time_frame>Immediately following the randomisation through Study Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Patients With ≥1 Asthma Exacerbation</title>
          <description>Number and percentage of patients with at least one post randomisation asthma exacerbation.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Asthma Exacerbation</title>
        <description>Time to the first occurrence of asthma exacerbation post randomisation</description>
        <time_frame>The time from randomisation to the date of first asthma exacerbation over 28 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Asthma Exacerbation</title>
          <description>Time to the first occurrence of asthma exacerbation post randomisation</description>
          <population>Full analysis set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">median survival time is not estimable due to number of exacerbations had not reached 50%.</measurement>
                    <measurement group_id="O2" value="NA">median survival time is not estimable due to number of exacerbations had not reached 50%.</measurement>
                    <measurement group_id="O3" value="155" lower_limit="111">Upper 95% CI for median is not estimable due to the curve representing the upper confidence limit of the survival function is above 50%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Including covariates treatment group, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Including covariates treatment group, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit</title>
        <description>Time to the first exacerbation requiring hospitalization or ER visit post randomisation</description>
        <time_frame>The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit</title>
          <description>Time to the first exacerbation requiring hospitalization or ER visit post randomisation</description>
          <population>Full analysis set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%.</measurement>
                    <measurement group_id="O2" value="NA">median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%.</measurement>
                    <measurement group_id="O3" value="NA">median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <method>Regression, Cox</method>
            <method_desc>Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Regression, Cox</method>
            <method_desc>Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Annualized Rate of Asthma Exacerbation</title>
        <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.</description>
        <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Annualized Rate of Asthma Exacerbation</title>
          <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.</description>
          <population>Full analysis set</population>
          <units>events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.55" upper_limit="1.26"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.34" upper_limit="0.88"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.33" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>negative binomial model</method>
            <method_desc>Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>negative binomial model</method>
            <method_desc>Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization</title>
        <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.</description>
        <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization</title>
          <description>The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.</description>
          <population>Full analysis set</population>
          <units>events/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.05" upper_limit="0.38"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.00" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.32" lower_limit="0.16" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>negative binomial model</method>
            <method_desc>Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>negative binomial model</method>
            <method_desc>Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days in Hospital Due to Asthma</title>
        <description>Number of days in hospital due to asthma, if none, 0 day is considered</description>
        <time_frame>The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days in Hospital Due to Asthma</title>
          <description>Number of days in hospital due to asthma, if none, 0 day is considered</description>
          <population>Full analysis set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.41" lower_limit="0.02" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.5" spread="3.86" lower_limit="0.00" upper_limit="0.08"/>
                    <measurement group_id="O3" value="1.2" spread="6.66" lower_limit="0.04" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Pre-bronchodilator FEV1</title>
        <description>Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Pre-bronchodilator FEV1</title>
          <description>Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" spread="0.429"/>
                    <measurement group_id="O2" value="0.255" spread="0.508"/>
                    <measurement group_id="O3" value="0.114" spread="0.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Total)</title>
        <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Total)</title>
          <description>Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="1.03"/>
                    <measurement group_id="O2" value="-0.77" spread="1.03"/>
                    <measurement group_id="O3" value="-0.58" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.947</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)</title>
        <description>Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)</title>
          <description>Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.56"/>
                    <measurement group_id="O2" value="-0.44" spread="0.52"/>
                    <measurement group_id="O3" value="-0.32" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)</title>
        <description>Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)</title>
          <description>Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.51"/>
                    <measurement group_id="O2" value="-0.34" spread="0.54"/>
                    <measurement group_id="O3" value="-0.27" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.973</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.480</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Rescue Medication Use</title>
        <description>Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of day inhaler puffs + 2 x [number of day nebulizer times].</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Rescue Medication Use</title>
          <description>Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of day inhaler puffs + 2 x [number of day nebulizer times].</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>number of puffs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="2.86"/>
                    <measurement group_id="O2" value="-2.58" spread="4.36"/>
                    <measurement group_id="O3" value="-1.07" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)</title>
        <description>Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)</title>
          <description>Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.697" spread="89.457"/>
                    <measurement group_id="O2" value="43.022" spread="73.303"/>
                    <measurement group_id="O3" value="10.884" spread="69.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.58</ci_lower_limit>
            <ci_upper_limit>45.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.26</ci_lower_limit>
            <ci_upper_limit>55.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)</title>
        <description>Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)</title>
          <description>Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.885" spread="83.136"/>
                    <measurement group_id="O2" value="34.157" spread="69.287"/>
                    <measurement group_id="O3" value="2.933" spread="72.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.237</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.08</ci_lower_limit>
            <ci_upper_limit>40.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>31.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.32</ci_lower_limit>
            <ci_upper_limit>56.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication</title>
        <description>Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication</title>
          <description>Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Proportion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.158" spread="0.283"/>
                    <measurement group_id="O2" value="-0.2" spread="0.337"/>
                    <measurement group_id="O3" value="-0.186" spread="0.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.742</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.693</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 28 in ACQ-6</title>
        <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 28 in ACQ-6</title>
          <description>ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of &lt;=0.75 indicates well-controlled asthma, scores between 0.75 to &lt;=1.5 indicate partly controlled asthma, and &gt;1.5 indicates not well controlled asthma.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.95"/>
                    <measurement group_id="O2" value="-1.09" spread="1.09"/>
                    <measurement group_id="O3" value="-0.68" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACQ-6 Responders (Improvement) at Week 28</title>
        <description>Improvement is defined as ACQ-6 (End of treatment - baseline) &lt;= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) &gt;= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>ACQ-6 Responders (Improvement) at Week 28</title>
          <description>Improvement is defined as ACQ-6 (End of treatment - baseline) &lt;= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) &gt;= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="0.95"/>
                    <measurement group_id="O2" value="46" spread="1.09"/>
                    <measurement group_id="O3" value="41" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.658</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.592</ci_lower_limit>
            <ci_upper_limit>2.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.661</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.826</ci_lower_limit>
            <ci_upper_limit>3.340</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)</title>
        <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
        <time_frame>Change from baseline at week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)</title>
          <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of &gt;=0.5 are considered clinically meaningful.</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.93"/>
                    <measurement group_id="O2" value="1.05" spread="1.04"/>
                    <measurement group_id="O3" value="0.67" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AQLQ(s)+12 Responders (Improvement) at Week 28</title>
        <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)&gt;=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) &lt;= -0.5.
Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.</description>
        <time_frame>Week 28</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>AQLQ(s)+12 Responders (Improvement) at Week 28</title>
          <description>AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)&gt;=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) &gt;-0.5 and &lt;0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) &lt;= -0.5.
Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="0.95"/>
                    <measurement group_id="O2" value="44" spread="1.09"/>
                    <measurement group_id="O3" value="39" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.220</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.538</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.773</ci_lower_limit>
            <ci_upper_limit>3.060</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.783</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.882</ci_lower_limit>
            <ci_upper_limit>3.605</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Exposure</title>
        <description>Duration of exposure from first dose date to last dose date.</description>
        <time_frame>From first dose to Week 24</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Exposure</title>
          <description>Duration of exposure from first dose date to last dose date.</description>
          <population>Safety analysis set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.53" spread="30.09"/>
                    <measurement group_id="O2" value="159.77" spread="35.781"/>
                    <measurement group_id="O3" value="167.05" spread="10.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of Benralizumab</title>
        <description>Pre-dose serum concentrations at each visit</description>
        <time_frame>Pre-first dose to Week 36</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Benralizumab</title>
          <description>Pre-dose serum concentrations at each visit</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=69, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Value is less than lower limit of quantification</measurement>
                    <measurement group_id="O2" value="NA">Value is less than lower limit of quantification</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=67, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="804.37" spread="52.77"/>
                    <measurement group_id="O2" value="721.42" spread="52.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 (n=66, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1152.96" spread="53.16"/>
                    <measurement group_id="O2" value="1019.65" spread="89.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=68, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1319.14" spread="66.05"/>
                    <measurement group_id="O2" value="1057.91" spread="125.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=67,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1337.98" spread="118.90"/>
                    <measurement group_id="O2" value="303.54" spread="144.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=65, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1162.62" spread="151.35"/>
                    <measurement group_id="O2" value="185.17" spread="278.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=65, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1125.96" spread="173.79"/>
                    <measurement group_id="O2" value="684.57" spread="205.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=2, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" spread="2140.87"/>
                    <measurement group_id="O2" value="5.92" spread="1230.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-drug Antibody Response</title>
        <description>Number and percentage of patients in different ADA response categories</description>
        <time_frame>From baseline to follow-up Week 36</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-drug Antibody Response</title>
          <description>Number and percentage of patients in different ADA response categories</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at any visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline and Post-baseline Postive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post-baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistently positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Blood Eosinophil Counts</title>
        <description>Percent change from baseline in blood eosinophil counts at week 28</description>
        <time_frame>Change from baseline at Week 28</time_frame>
        <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Blood Eosinophil Counts</title>
          <description>Percent change from baseline in blood eosinophil counts at week 28</description>
          <population>Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-97.4" spread="12.93"/>
                    <measurement group_id="O2" value="-94.9" spread="16.54"/>
                    <measurement group_id="O3" value="45.5" spread="239.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline eosinophil count, region, visit, treatment by visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-162.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-220.1</ci_lower_limit>
            <ci_upper_limit>-104.3</ci_upper_limit>
            <estimate_desc>Percent change</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Include covariates: treatment group, baseline eosinophil count, region, visit, treatment by visit.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-159.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-217.9</ci_lower_limit>
            <ci_upper_limit>-100.9</ci_upper_limit>
            <estimate_desc>Percent change</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lung Capacity</title>
        <description>Change from baseline in total lung capacity</description>
        <time_frame>From baseline to Week 28</time_frame>
        <population>Global Sputum Substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lung Capacity</title>
          <description>Change from baseline in total lung capacity</description>
          <population>Global Sputum Substudy</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=17, 23, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.95"/>
                    <measurement group_id="O2" value="-0.07" spread="0.68"/>
                    <measurement group_id="O3" value="-0.30" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=14, 18, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="1.31"/>
                    <measurement group_id="O2" value="-0.21" spread="0.70"/>
                    <measurement group_id="O3" value="-0.47" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume</title>
        <description>Change from baseline in residual volume</description>
        <time_frame>From baseline to Week 28</time_frame>
        <population>Global Sputum Substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume</title>
          <description>Change from baseline in residual volume</description>
          <population>Global Sputum Substudy</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=17, 23, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.00"/>
                    <measurement group_id="O2" value="-0.22" spread="0.74"/>
                    <measurement group_id="O3" value="-0.35" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=14, 18, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.34"/>
                    <measurement group_id="O2" value="-0.31" spread="0.71"/>
                    <measurement group_id="O3" value="-0.41" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Capacity</title>
        <description>Change from baseline in vital capacity</description>
        <time_frame>From baseline to Week 28</time_frame>
        <population>Global Sputum Substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Capacity</title>
          <description>Change from baseline in vital capacity</description>
          <population>Global Sputum Substudy</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=17, 24, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.80"/>
                    <measurement group_id="O2" value="0.18" spread="0.35"/>
                    <measurement group_id="O3" value="0.13" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=14, 18, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.41"/>
                    <measurement group_id="O2" value="0.11" spread="0.48"/>
                    <measurement group_id="O3" value="-0.08" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Residual Capacity</title>
        <description>Change from baseline in functional residual capacity</description>
        <time_frame>From baseline to Week 28</time_frame>
        <population>Global Sputum Substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Residual Capacity</title>
          <description>Change from baseline in functional residual capacity</description>
          <population>Global Sputum Substudy</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=17,23, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.06"/>
                    <measurement group_id="O2" value="-0.09" spread="0.74"/>
                    <measurement group_id="O3" value="-0.38" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=13,18, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.49"/>
                    <measurement group_id="O2" value="-0.26" spread="0.74"/>
                    <measurement group_id="O3" value="-0.43" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity</title>
        <description>Change from baseline in inspiratory capacity</description>
        <time_frame>From baseline to Week 28</time_frame>
        <population>Global Sputum Substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg q.4 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 30 mg q.8 Weeks</title>
            <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity</title>
          <description>Change from baseline in inspiratory capacity</description>
          <population>Global Sputum Substudy</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=17, 23, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.22"/>
                    <measurement group_id="O2" value="0.14" spread="0.88"/>
                    <measurement group_id="O3" value="-0.01" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=14, 17, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.16"/>
                    <measurement group_id="O2" value="0.09" spread="1.01"/>
                    <measurement group_id="O3" value="-0.02" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Include events occurred from the start of study treatment to the end of study (up to 36 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Benra 30 mg q.4 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Benra 30 mg q.8 Weeks</title>
          <description>Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ’s Confidential Information without AZ’s written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Goldman, Global Clinical Lead Benralizumab</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 301 398 0323</phone>
      <email>Mitchell.Goldman@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

